Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Senti Biosciences ( (SNTI) ) has issued an announcement.
Senti Biosciences reported encouraging initial results from a Phase 1 clinical trial of SENTI-202, an innovative CAR-NK cell therapy targeting hematologic malignancies like AML. Two out of three patients achieved complete remission at the initial dose, showing no detectable cancer cells, with the therapy being well-tolerated. The trial continues with dose escalation and further data expected in 2025, offering hope for patients with limited treatment options.
Find detailed analytics on SNTI stock on TipRanks’ Stock Analysis page.
Trending Articles
- ‘Time to Jump Ship,’ Says Investor About MicroStrategy Stock
- Nvidia and Microsoft: Why This Top Investment Firm Decided to Dump Shares
- Wells Fargo (NYSE:WFC) Departs Philadelphia Sports Arena
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
